

The growing evidence behind the connection between infections and cancer (Part 2)

AONM webinar 6th September 2022

Armin Schwarzbach MD PhD

**Medical doctor and Specialist for laboratory medicine
Augsburg, Germany**

ArminLabs

Laboratory for tick-borne diseases

Tel. 0049 821 2182879

info@arminlabs.com

www.arminlabs.com



www.aonm.org

0044 333 121 0305



This follows on from Part 1 last month

<https://aonm.org/view-past-webinars/>



DR. ARMIN
SCHWARZBACH

PDF OF SLIDE PRESENTATION

THE GROWING EVIDENCE BETWEEN INFECTIONS AND CANCER (PART 1)

Dr. Armin Schwarzbach: The Growing Evidence Between Infections and Cancer, P.1

Blood cancers and EBV: Seminal research at the University of Sussex – important genetic implications

MYC activation and BCL2L1 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs

Epstein-Barr virus (EBV) is associated with the development of numerous lymphomas including Burkitt's (BL), post-transplant, Hodgkin's and certain NK and T-cell lymphomas

Professor West said: "This is a key step towards uncovering how this common virus which affects thousands of people every year, causes blood cancer."


Source: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920234/pdf/wmlr14270.pdf>

Watch on: YouTube arminlabs

This document is intellectual property of Armin Schwarzbach MD PhD. Reproduction only with permission. Please note the copyright.

- Breast cancer
- Monoclonal Gammopathy
- Prostate cancer
- Blood cancers
- Glioblastoma

Lung, liver, stomach and bowel the most common causes of cancer death worldwide



The screenshot shows the Cancer Research UK website. At the top is the logo with the text "CANCER RESEARCH UK" and the slogan "Together we will beat cancer". There is a search bar and a "Donate" button. A navigation menu includes "About cancer", "Get involved", "Our research", "Funding for researchers", "Shop", and "About us".

The main content area features a purple header for "Mortality worldwide". Below it, a list of bullet points states:

- There were 9.6 million deaths from cancer worldwide in 2018.
- Lung, liver, stomach, and bowel are the most common causes of cancer death worldwide, accounting for more than four in ten of all cancer deaths.
- Lung, liver, stomach and bowel cancers have been the four most common causes of cancer death since 1975.
- UK mortality is ranked lower than two-thirds of Europe.
- UK mortality is ranked higher than two-thirds of the world.

A link "Read more in-depth worldwide cancer mortality statistics" is provided. Below this is a purple header for "Risk factors worldwide".

Under "Risk factors worldwide", there are two sections:

- Statistics for all cancers combined in the UK**: Includes links for Incidence, Mortality, Survival, Risk, and Screening and diagnosis.
- Statistics by cancer type**: Includes text about cancer incidence, mortality, survival, and risk factors, and a list of cancer types: Breast cancer, Lung cancer, Prostate cancer, and Bowel cancer. A dropdown menu "Select a cancer type" is also visible.

Source:
<https://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer#heading-One>

What cancers have infections been associated with?

Part 2:

- ▶ Lung
- ▶ Colorectal
- ▶ Gastric
- ▶ Oesophageal
- ▶ Cervical
- ▶ Liver

What cancers have infections been associated with?

Part 2:

- ▶ Lung
- ▶ Colorectal
- ▶ Gastric
- ▶ Oesophageal
- ▶ Cervical
- ▶ Liver

Lung cancer is the leading cause of cancer death worldwide



“Tobacco smoke environmental factors such as arsenic, radon or asbestos Additionally, **the involvement of some viral infections such as high-risk human papillomaviruses (HR-HPVs), Merkel cell polyomavirus (MCPyV), Jaagsiekte Sheep Retrovirus (JSRV), John Cunningham Virus (JCV), and Epstein–Barr virus (EBV)**”

Source: Osorio JC, Blanco R, Corvalán AH, Muñoz JP, Calaf GM, Aguayo F. Epstein-Barr Virus Infection in Lung Cancer: Insights and Perspectives. *Pathogens*. 2022 Jan 21;11(2):132.

Viral oncogenes in EBV can activate various tumour-associated pathways



Review

Pathogenic Role of Epstein-Barr Virus in Lung Cancers

David Becnel ^{1,†}, Ramsy Abdelghani ^{1,†}, Asuka Nanbo ^{2,†}, Janardhan Avilala ³, Jacob Kahn ³, Li Li ^{4,*} and Zhen Lin ^{3,5}

¹ Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA 70112, USA; dbecnel@tulane.edu (D.B.); rabdelgh@tulane.edu (R.A.)

² National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University, Sakamoto, Nagasaki 852-8523, Japan; nanbo@nagasaki-u.ac.jp

³ Department of Pathology and Laboratory Medicine, Tulane University Health Sciences Center and Tulane Cancer Center, New Orleans, LA 70112, USA; j.avilala@tulane.edu (J.A.); jkahn@tulane.edu (J.K.)

⁴ Institute of Translational Research, Ochsner Clinic Foundation, New Orleans, LA 70112, USA; lili@ochsner.org

⁵ Correspondence: zlin@tulane.edu; Tel.: +1-504-888-1506

[†] These authors have contributed equally to this work.

Abstract: Human oncogenic viruses account for at least 12% of total cancer cases worldwide. Epstein-Barr virus (EBV) is the first identified human oncogenic virus and it alone causes ~200,000 cancer cases and ~1.8% of total cancer-related death annually. Over the past 40 years, increasing lines of evidence have supported a causal link between EBV infection and a subgroup of lung cancers (LCs). In this article, we review the current understanding of the EBV-LC association and the etiological role of EBV in lung carcinogenesis. We also discuss the clinical impact of the knowledge gained from previous research, challenges, and future directions in this field. Given the high clinical relevance of EBV-LC association, there is an urgent need for further investigation on this topic.

Keywords: non-small cell lung cancer; NSCLC; small cell lung cancer; SCLC; Epstein-Barr virus; EBV; next-generation sequencing; NGS

1. Lung Cancers

Lung cancers (LCs) are the number one killer among cancers in the U.S. and estimated to cause more than 131,000 deaths in 2021 [1]. With more than 200,000 annual cases in the U.S., LCs have remained as the second most common cancers in both men and women for

Table 1. EBV gene expression in different types of latency.

Latency Types	EBV Genes	Examples of EBV Associated Cancers
0	EBER1, EBER2, RPMS1, viral miRNAs	Memory B cells in EBV(+) individuals
I	EBER1, EBER2, RPMS1, viral miRNAs, and EBNA1	Burkitt's lymphoma
II	EBER1, EBER2, RPMS1, viral miRNAs, EBNA1, LMP1, LMP2A, and LMP2B	Nasopharyngeal carcinoma Lung cancer
III	EBER1, EBER2, RPMS1, viral miRNAs, EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, EBNA-LP, LMP1, LMP2A, and LMP2B	AIDS-associated lymphoma

Accumulating evidence has shown that both viral latency and lytic cycle are required for EBV pathogenesis. There are approximately 100 open reading frames encoded by the EBV genome. Among them, some latent genes such as EBV-encoded nuclear antigen 1 (EBNA1) [21], EBV-encoded nuclear antigen 2 (EBNA2), EBV-encoded nuclear antigen 3C (EBNA3C), and latent membrane protein 1 (LMP1) have been shown to mediate viral oncogenesis in cell and/or animal models. These viral oncogene products can activate various tumor-associated pathways such as Notch and nuclear factor- κ B (NF- κ B) signalings. In addition to well-characterized viral protein-coding genes, EBV has been shown to utilize viral non-coding RNAs (ncRNAs) such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), small non-coding EBV-encoded RNAs (EBERs), as well as recently identified circular RNA (circRNA) to facilitate its life cycle and oncogenesis [22–30].

“Both viral latency and the lytic cycle are required for EBV pathogenesis”

Source: Kheir F, Zhao M, Strong MJ, Yu Y, Nanbo A, Flemington EK, Morris GF, Reiss K, Li L, Lin Z. Detection of Epstein-Barr Virus Infection in Non-Small Cell Lung Cancer. *Cancers* (Basel). 2019 May 31;11(6):759.; Becnel D, Abdelghani R, Nanbo A, Avilala J, Kahn J, Li L, Lin Z. Pathogenic Role of Epstein-Barr Virus in Lung Cancers. *Viruses*. 2021 May 11;13(5):877.

Chlamydia pneumoniae is significantly related to the risk of lung carcinoma

TCR TRANSLATIONAL CANCER RESEARCH
ADVANCES CLINICAL MEDICINE TOWARD THE GOAL OF IMPROVING PATIENTS' QUALITY OF LIFE

Home Journal Info For Authors For Reviewer Special Contents Current Issue Archives Online First News

Home / Vol 8, No 8 (December 2019) / Association between *Chlamydia pneumoniae* infection and lung cancer: a meta-analysis

Original Article [Check for updates](#)

Association between *Chlamydia pneumoniae* infection and lung cancer: a meta-analysis

Chunxi Wang, Naxin Zhang, Liang Gao

Department of Respiration, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, Tianjin 300170, China

Contributions: (I) Conception and design: All authors; (II) Administrative support: N Zhang; (III) Provision of study materials or patients: N Zhang; (IV) Collection and assembly of data: C Wang, N Zhang; (V) Data analysis and interpretation: All authors; (VI) Manuscript preparation: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Naxin Zhang, Department of Respiration, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Institute of Hepatobiliary Disease, The Third Central Hospital of Tianjin, No. 83, Jintang Road, Hedong District, Tianjin 300170, China. Email: zhangnaxin801@163.com

Background: The aim of this study is to explore the correlation between *Chlamydia pneumoniae* (*C. pneumoniae*) infection and lung carcinoma.

Methods: Databases of PubMed, Embase, Embase, Ovid, Wanfang and China National Knowledge Infrastructure (CNKI) database were investigated for eligible literatures from their establishments to February, 2019. Included studies were selected according to specific eligibility criteria. Statistical analysis was performed by RevMan 5.3 software.

“Results showed that **C. pneumoniae infection was significantly related to the risk of lung carcinoma**, with a 3.19-fold increased risk compared to a negative titre (95% CI, 1.96–5.19) for IgA and 2.02 times (95% CI, 1.29–3.16) for IgG”

Source: Wang C, Zhang N, Gao L. Association between *Chlamydia pneumoniae* infection and lung cancer: a meta-analysis. Transl Cancer Res. 2019 Dec;8(8):2813-2819.

Chlamydia pneumoniae: “Elevated antibody titers associated with significantly increased risk”

Cancer Epidemiology, Biomarkers & Prevention

Home About Articles For Authors Alerts

Research Articles

Chlamydia pneumoniae Infection and Risk for Lung Cancer

Anil K. Chaturvedi, Charlotte A. Gaydos, Patricia Agreda, Jeffrey P. Holden, Nilanjan Chatterjee, James J. Goedert, Neil E. Caporaso, and Eric A. Engels
DOI: 10.1158/1055-9965.EPI-09-1261 Published June 2010

Article Figures & Data Info & Metrics PDF

Abstract

Background: We evaluated the relationship of *Chlamydia pneumoniae* infection with prospective lung cancer risk using traditional serologic markers [microimmunofluorescence (MIF) IgG and IgA antibodies] and *Chlamydia* heat shock protein-60 (CHSP-60) antibodies, a marker for chronic chlamydial infection.

Methods: We conducted a nested case-control study (593 lung cancers and 671 controls) within the screening arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial ($N = 77,464$). Controls were matched to cases by age, sex, randomization year, follow-up time, and smoking (pack-years of smoking, time since quitting). We assessed *C. pneumoniae* seropositivity and endpoint antibody titers (IgG and IgA against *C. pneumoniae* elementary bodies and IgG against CHSP-60).

Results: *C. pneumoniae* seropositivity by microimmunofluorescence IgG or IgA antibodies was not associated with lung cancer [odds ratio of 0.88 and 95% confidence interval (95% CI) of 0.69–1.13 for IgG, odds ratio of 0.98 and 95% CI of 0.75–1.27 for IgA]. In contrast, individuals seropositive for CHSP-60 IgG antibodies had significantly increased lung cancer risk (odds ratio, 1.30; 95% CI, 1.02–1.67), and risk increased with increasing antibody titers (P trend = 0.005). CHSP-60-related risk did not differ significantly by lung cancer histology, follow-up time, or smoking. CHSP-60

“CHSP-60 seropositivity and elevated antibody titers were associated with significantly increased risk for subsequent lung cancer, supporting an etiologic role for *C. pneumoniae* infection in lung carcinogenesis.”

“Our results highlight the potential for lung cancer risk reduction through treatments targeted toward *C. pneumoniae* infections and chronic pulmonary inflammation.”

Source: <https://aacrjournals.org/cebpa/article/19/6/1498/68420/Chlamydia-pneumoniae-Infection-and-Risk-for-Lung>

Thirteen studies with 2,553 lung carcinoma cases and 2,460 controls



“One mechanism is through mediators of inflammation. Inflammation gives rise to reactive oxygen species that may cause damage to DNA. Inflammation causes cell injury, resulting in consequent cell repair, increasing the rate of cell division ... higher cell turnover will increase the risk of a mutation, conferring a selective advantage to cells, leading to cancer.”

Source: Premachandra NM, Jayaweera JAAS. Chlamydia pneumoniae infections and development of lung cancer: systematic review. Infect Agent Cancer. 2022 Mar 22;17(1):11.

Mycoplasma infection in lung cancer was 52.6% in this study

medRxiv preprint doi: <https://doi.org/10.1101/2021.04.15.21255534>; this version posted April 15, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.



World J Gastroenterol. 2001 Apr 15; 7(2): 296-299.
Published online 2001 Apr 15; doi: 10.3748/wjg.v7.i2.296

PMCID: PMC4723534

Mycoplasma infections and different human carcinomas

Su Huang, Ji You Li, Jian Wu, Lin Meng, and Cheng-Chao Shou

Author information ► Article notes ► Copyright and License information ►

This article has been cited by other articles in PMC.

Abstract

Go to:

AIM: To explore relationships between human carcinomas and mycoplasma infection.

METHODS: Monoclonal antibody PD4, which specifically recognizes a distinct protein from mycoplasma hyorhinis, was used to detect mycoplasma infection in different paraffin embedded carcinoma tissues with immunohistochemistry. PCR was applied to amplify the mycoplasma DNA from the positive samples for confirming immunohistochemistry.

RESULTS: Fifty of 90 cases (56%) of gastric carcinoma were positive for mycoplasma hyorhinis. In other gastric diseases, the mycoplasma infection ratio was 28% (18/49) in chronic superficial gastritis, 30% (14/46) in gastric ulcer and 37% (18/49) in intestinal metaplasia. The difference is significant with gastric cancer ($\chi^2 = 12.06$, $P < 0.05$). In colon carcinoma, the mycoplasma infection ratio was 55.1% (32/58), but it was 20.9% (10/49) in adenomatous polyp ($\chi^2 = 13.46$, $P < 0.005$). Gastric and colon cancers with high differentiation had a higher mycoplasma infection ratio than those with low differentiation ($P < 0.05$).

“There was high correlation between mycoplasma infection and different cancers, which suggests the possibility of an association between the two.”

Table 1 Mycoplasma infection in different grades of gastric carcinoma.

Grades of differentiation	Total number of cases	Negative cases (-)	Positive cases		Total positive cases	Ratio of positive (%)
			(+)	(++)		
I-II	23	3	12	8	20	87
II-III	18	7	9	2	11	61
III	49	30	14	5	17	39
Total	90	40	35	14	50	56

Table 2 Mycoplasma infection in different grades of colon carcinoma.

Grades of differentiation	Total number of cases	Negative cases (-)	Positive cases		Total positive cases	Ratio of positive (%)
			(+)	(++)		
I-II	42	15	15	12	27	64
II-III	8	5	2	1	3	37
III	8	6	2	0	2	30
Total	58	26	19	13	32	55 (mean)

Table 4 Mycoplasma infection in other carcinoma tissues.

Types of carcinoma	Total number of cases	Negative cases (-)	Positive cases		Total positive cases	Ratio of positive (%)
			(+)	(++)		
Esophagus	53	26	21	6	27	50.9
Lung	59	28	23	8	31	52.6
Breast	63	36	17	8	25	39.7
Glioma	91	53	27	11	38	41.8
Total	266	145	88	33	121	45.5

Source: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723534/>

This document is intellectual property of Armin Schwarzbach MD PhD.
Reproduction only with permission. Please note the copyright.

Mycoplasma pneumoniae infection induces reactive oxygen species and DNA damage, especially to the mitochondria



AMERICAN
SOCIETY FOR
MICROBIOLOGY

Infection and
Immunity

HOME | CURRENT ISSUE | ARCHIVE | ALERTS | ABOUT ASM | CONTACT US | TECH SUPPORT | J

Mycoplasma pneumoniae Infection Induces Reactive Oxygen Species and DNA Damage in A549 Human Lung Carcinoma Cells*



Gongping Sun¹, Xuefeng Xu², Yingshuo Wang², Xiaoyun Shen¹, Zhimin Chen^{2,*} and Jun Yang^{1,3,4,*}

+ Author Affiliations

ABSTRACT

Mycoplasma pneumoniae is a frequent cause of community-acquired bacterial respiratory infections in children and adults. In the present study, using a proteomic approach, we studied the effects of *M. pneumoniae* infection on the protein expression profile of A549 human lung carcinoma cells. *M. pneumoniae* infection induced changes in the expression of cellular proteins, in particular a group of proteins involved in the oxidative stress response, such as glucose-6-phosphate 1-dehydrogenase, NADH dehydrogenase (ubiquinone) Fe-S protein 2, and ubiquinol-cytochrome *c* reductase complex core protein I mitochondrial precursor. The oxidative status of *M. pneumoniae*-infected cells was evaluated,

“*M. pneumoniae* infection induced changes in the expression of cellular proteins, in particular a group of proteins involved in the oxidative stress response, such as glucose-6-phosphate 1-dehydrogenase, NADH dehydrogenase (ubiquinone) Fe-S protein 2, and ubiquinol-cytochrome *c* reductase complex core protein I mitochondrial precursor ... It was further shown that *M. pneumoniae* infection also induced DNA double-strand breaks, as demonstrated by the formation of H2AX foci. On the other hand, an ROS scavenger, N-acetylcysteine, could inhibit the ROS generation ..”

Connections between lung cancer and SARS-CoV-2 now being investigated: vulnerability already detected

Journal of Thoracic Oncology | IASLC International Association for the Study of Lung Cancer

Log in at IASLC Claim | Submit | Log in | Register | Subscribe | Search | Menu

STATE OF THE ART: CONCISE REVIEW SARS-COV-2 COLLECTION | VOLUME 17, ISSUE 2
P214-227, FEBRUARY 01, 2022

Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation

Christian Rolfo, PhD, MD, MBA, Drhc • Noy Meshulam, BSc • Alessandro Russo, MD, PhD • ...
Paul A. Bunn Jr., MD, PhD • John D. Minna, MD, PhD • Fred R. Hirsch, MD, PhD, FASCO

Show all authors

Published: November 10, 2021 • DOI: <https://doi.org/10.1016/j.jtho.2021.11.001> • Check for updates

PDF [666 KB] | Figures | Save | Share | Reprints | Request

PhumX Metrics

Abstract

Patients with lung cancer are especially vulnerable to coronavirus disease 2019 (COVID-19) with a greater than sevenfold higher rate of becoming infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19, a greater than threefold higher hospitalization rate with high complication rates, and an estimated case fatality rate of more than 30%. The reasons for the increased vulnerability are not

Abstract | Keywords | Introduction | Biological Context: COVID-19 and Lung Cancer | Clinical Implications of

[https://www.jto.org/article/S1556-0864\(21\)03209-8/fulltext#pagebody](https://www.jto.org/article/S1556-0864(21)03209-8/fulltext#pagebody)

ADVERTISEMENT

IASLC FOUNDATION

The IASLC Foundation supports the education of fellows and young investigators who will be the next generation of lung cancer physicians and scientists.

Help others succeed

Click Here for more information

Source: Rolfo C et al. Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. J Thorac Oncol. 2022 Feb;17(2):214-227.

Tailored testing protocol for the possibility of infection-associated lung cancer

» Lung cancer:

1. Chlamydia pneumoniae EliSpot + IgG/IgA antibodies
2. Mycoplasma pneumoniae EliSpot + IgG/IgA antibodies
3. EBV EliSpot

What cancers have infections been associated with?

Part 2:

- ▶ Lung
- ▶ **Colorectal**
- ▶ Gastric
- ▶ Oesophageal
- ▶ Cervical
- ▶ Liver


A number of bacteria implicated in the development of colorectal cancer



“Several **bacteria** have been identified and implicated in the development of CRC. These include: *Streptococcus bovis*, *Helicobacter pylori*, *E. coli*, *Klebsiella pneumoniae*, and more recently, *Fusobacterium*.”

Source: Antonic V, Stojadinovic A, Kester KE, Weina PJ, Brücher BL, Protic M, Avital I, Izadjoo M. Significance of infectious agents in colorectal cancer development. J Cancer. 2013;4(3):227-40.

... as well as several viruses: EBV, HPV, CMV and JCV



“EBV and HPV, together with cytomegalovirus (CMV or human herpesvirus type 5) and John Cunningham virus (JCV), have been consistently reported to be prevalent in CRC.”

Source: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978519/pdf/MOL2-16-1423.pdf>

Cytomegalovirus detected in 42.3% of colorectal tumor specimens in this 2012 study

> J Clin Virol. 2012 Jul;54(3):240-4. doi: 10.1016/j.jcv.2012.04.007. Epub 2012 May 15.

Human cytomegalovirus preferentially infects the neoplastic epithelium of colorectal cancer: a quantitative and histological analysis

Hsin-Pai Chen¹, Jeng-Kai Jiang, Cheng-Yu Chen, Teh-Ying Chou, Yen-Chung Chen, Ya-Ting Chang, Shou-Fu Lin, Chia-Hao Chan, Chih-Yung Yang, Chi-Hung Lin, Jen-Kou Lin, Wen-Long Cho, Yu-Jiun Chan

Affiliations + expand

PMID: 22595308 DOI: 10.1016/j.jcv.2012.04.007

Abstract

Background: It has long been suggested that human cytomegalovirus (HCMV) might be involved in human oncogenesis. However, whether HCMV was associated with colorectal cancer (CRC) was still controversial.

Objective: To clarify whether HCMV specifically infects the tumorous tissue of CRC.

Study design: Paired tumor and adjacent non-neoplastic CRC specimens were collected from 163 patients. HCMV DNA was detected and quantified through PCR and quantitative real-time PCR. Virus location was determined by in situ hybridization (ISH) of formalin-fixed paraffin-embedded tissue sections with an HCMV-specific probe.

Results: By PCR, HCMV DNA was detected in 42.3% (69/163) of the tumor specimens, while only 5.6% (14/163) samples of adjacent non-neoplastic tissue were positive for HCMV ($p < 0.0001$). Quantitative real-time PCR in 54 sample pairs revealed significantly higher viral copies in the tumor specimens than the adjacent non-neoplastic tissue specimens ($p < 0.001$). By ISH, the nucleic acids of HCMV were detected in the cytoplasm of neoplastic epithelium. No hybridization was detected in the inflammatory infiltrates, submucosa, or other stromal tissues.

Conclusions: HCMV preferentially infects the tumor epithelium of CRC. How the virus subsists in and interacts with the microenvironment of tumor epithelium of CRC should be studied.

Copyright © 2012 Elsevier B.V. All rights reserved.

163 specimens: “HCMV DNA was detected in 42.3% (69/163) of the tumor specimens”

Source: Chen HP, Jiang JK, Chen CY, Chou TY, Chen YC, Chang YT, et al. Human cytomegalovirus preferentially infects the neoplastic epithelium of colorectal cancer: a quantitative and histological analysis. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2012;54(3):240-4.

Tailored testing protocol for the possibility of infection-associated colorectal cancer

» Colorectal cancer:


1. H. pylori IgG/IgA
2. EBV EliSpot
3. CMV EliSpot

What cancers have infections been associated with?

Part 2:

- ▶ Lung
- ▶ Colorectal
- ▶ **Gastric**
- ▶ Oesophageal
- ▶ Cervical
- ▶ Liver

Gastric cancer and H pylori/Epstein Barr Virus



“In the past decades, *Helicobacter pylori* and Epstein Barr virus infections have been identified and confirmed to be causal factors of gastric cancer.”

“EBV-positive gastric cancer often occurs in the proximal stomach (cardia and gastric body), where it forms lumps or ulcers that are accompanied by lymphocyte infiltration. Another noteworthy feature of EBV-positive gastric cancer is the ease of invasion into the submucosa, with a low rate of lymph node metastasis.”

Source: 1. <https://pubmed.ncbi.nlm.nih.gov/25186851/>; 2. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769310/pdf/fonc-10-583463.pdf>;
Selgrad M et al. (2008) The role of viral and bacterial pathogens in gastrointestinal cancer. *J Cell Physiol* 216, 378–388; Costa N, Gil da Costa R & Medeiros R (2018) A viral map of gastrointestinal cancers. *Life Sci* 199, 188–200.

EBV is the causal agent of a subset of gastric carcinomas

J Clin Pathol/ Med Pathol 2000;53:255-261

255

Epstein-Barr virus and gastric carcinoma

K Takada

Abstract

The Epstein-Barr virus (EBV) is detected in the tissue of about 10% of gastric carcinoma cases throughout the world. In each case, 100% of carcinoma cells are infected with EBV. Analysis of EBV in carcinoma biopsies indicates that carcinoma is formed by the proliferation of a single EBV infected cell. These findings suggest that EBV plays an important role in the development of EBV positive gastric carcinomas. The EBV genes expressed are EBV determined nuclear antigen 1 (EBNA1), two small non-polyadenylated RNAs known as EBER1 and EBER2, and the transcripts from the BamHI-A region (BARF0); in addition, some cases also express a small amount of latent membrane protein 2A (LMP2A). Epithelial cells are refractory to EBV infection in vitro. This has hampered the study of the role of EBV in epithelial malignancies. The use of recombinant EBV carrying a selectable marker has enabled this difficulty to be overcome. EBV infected cell clones can be obtained from most carcinoma cell lines examined, and it was found that cell to cell contact was an efficient mode of EBV infection. Furthermore, it was possible to immortalise primary gastric epithelial cells by EBV infection. The cells expressed identical EBV genes to those typically seen in EBV positive gastric carcinoma, and showed accelerated malignant properties, including growth in soft agarose and tumorigenicity in severe combined immunodeficient (SCID) mice. These re-

carcinomas, and the worldwide occurrence of EBV positive gastric carcinoma is estimated at more than 50 000 cases/year.

Unlike B cells, epithelial cells have displayed a remarkable resistance to EBV infection in vitro. This has hampered the study of the role of EBV in the development of epithelial malignancies. Therefore, we have established a system for the infection of epithelial cells in vitro, which has allowed us to study the role of EBV in the development of epithelial malignancies. Here, I review the literature concerning the association of EBV and gastric carcinoma, and introduce our recent findings obtained using our system for the infection of epithelial cells.

Epidemiology

Most nasopharyngeal carcinomas are undifferentiated and accompanied by intense lymphoid infiltration (termed lymphoepithelioma). Carcinomas with a similar histological profile occur at a low incidence in organs such as the salivary glands, thymus, lungs, etc, mainly in Chinese and Inuits. These carcinomas are termed lymphoepithelioma-like carcinomas or carcinomas with lymphoid stroma, and most cases are EBV positive.¹ The association between EBV and gastric carcinoma was first reported in this particular type of gastric carcinoma.¹ EBV DNA was demonstrated in more than 80% of gastric carcinomas of the lymphoepithelioma type by PCR and ISH.²⁻⁴ Subsequently, Shibata and Weiss demonstrated EBV infection in gastric adenocarcinomas of ordinary histology (fig 1).⁵ They reported that EBV is present in almost all carcinoma cells in

“The Epstein-Barr virus (EBV) is detected in the tissue of about 10% of gastric carcinoma cases throughout the world. In each case, 100% of carcinoma cells are infected with EBV. Analysis of EBV in carcinoma biopsies indicates that carcinoma is formed by the proliferation of a single EBV infected cell.”

Source: Tokunaga, M.; Land, C.E.; Uemura, Y.; Tokudome, T.; Tanaka, S.; Sato, E. Epstein-Barr virus in gastric carcinoma. *Am. J. Pathol.* 1993, 143, 1250–1254; Osorio JC, Blanco R, Corvalán AH, Muñoz JP, Calaf GM, Aguayo F. Epstein-Barr Virus Infection in Lung Cancer: Insights and Perspectives. *Pathogens.* 2022 Jan 21;11(2):132.

Tailored testing protocol for the possibility of infection-associated gastric cancer

» Gastric cancer:

1. H. pylori IgG/IgA
2. EBV EliSpot

What cancers have infections been associated with?

Part 2:

- ▶ Lung
- ▶ Colorectal
- ▶ Gastric
- ▶ **Oesophageal (Barrett's Syndrome)**
- ▶ Cervical
- ▶ Liver

Mycoplasma infection in oesophageal cancer was 50.9% in this study

World J Gastroenterol 2001 Apr 15; 7(2): 266-269



World J Gastroenterol 2001 Apr 15; 7(2): 266-269

Published online 2001 Apr 15. doi: 10.3748/wjg.v7.i2.266

Mycoplasma infections and different human carcinomas

Su Huang, Ji-You Li, Jian Wu, Lin Meng, and Cheng-Chao Shou

Author information: ► Article notes: ► Copyright and license information: ►

This article has been cited by other articles in PMC.

Abstract

AIM: To explore relationships between human carcinomas and mycoplasma infection.

METHODS: Monoclonal antibody PD4, which specifically recognizes a distinct protein mycoplasma hyorhinis, was used to detect mycoplasma infection in different paraffin embedded tissues with immunohistochemistry. PCR was applied to amplify the mycoplasma DNA samples for confirming immunohistochemistry.

RESULTS: Fifty of 90 cases (56%) of gastric carcinoma were positive for mycoplasma in gastric diseases, the mycoplasma infection ratio was 28% (18/49) in chronic superficial gastritis (14/46) in gastric ulcer and 37% (18/49) in intestinal metaplasia. The difference is significant cancer ($\chi^2 = 12.06, P < 0.05$). In colon carcinoma, the mycoplasma infection ratio was 51% (10/49) in adenomatous polyp ($\chi^2 = 13.46, P < 0.005$). Gastric and colon cancer differentiation had a higher mycoplasma infection ratio than those with low differentiation.

than that of low differentiation colon carcinoma tissues (Table 3, $P < 0.05$).

In the 49 cases of adenomatous polyp, there were 10 cases with mycoplasma infection. The positive ratio was 20.4%. The difference between the infection ratio of colon carcinoma and that of adenomatous polyp was significant ($\chi^2 = 13.46, P < 0.005$).

Table 3 Mycoplasma infection in different grades of colon carcinoma

Grades of differentiation	Total number of cases	Negative cases (-)	Infection of mycoplasma			
			Positive cases		Total positive cases	Ratio of positive (%)
			(+)	(++)		
I-II	42	15	15	12	27	64
II-III	8	5	2	1	3	37
III	8	6	2	0	2	30
Total	58	26	19	13	32	55 (mean)

Mycoplasma infection in other carcinoma tissues

Beside the gastrointestinal carcinomas, other cancer tissues from human esophagus, lung, breast and brain were also analyzed (Table 4).

Table 4 Mycoplasma infection in other carcinoma tissues

Types of carcinoma	Total number of cases	Negative cases (-)	Infection of mycoplasma		Total positive cases	Ratio of positive (%)
			Positive cases			
			(+)	(++)		
Esophagus	53	26	21	6	27	50.9
Lung	59	28	23	8	31	52.5
Breast	63	38	17	8	25	39.7
Glioma	91	53	27	11	38	41.0
Total	266	145	88	33	121	45.5

Some immunoperoxidase stainings of different carcinoma are shown in Figure 1. The low differential gastric cancer (ring cell cancer) was negative reacted with PD4




Figure 1 Immunoperoxidase stainings of different carcinoma tissues reacted with monoclonal antibody PD4 ($\times 400$). Both A and B were gastric carcinomas. A (signet-ring cell carcinoma) was negative, B (adenocarcinoma) was positive. C (glioma) indicated the negative reaction, D (glioma), E (lung cancer), F (esophagus cancer), G (breast cancer) and H (colon cancer) presented the positive reactions with antibody PD4.



Source: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723534/>

Tailored testing protocol for the possibility of infection-associated oesophageal cancer

» Oesophageal cancer:

1. Mycoplasma pneumoniae Elispot and IgG/IgA antibodies
2. H. pylori IgG/IgA

What cancers have infections been associated with?

Part 2:

- ▶ Lung
- ▶ Colorectal
- ▶ Gastric
- ▶ Oesophageal
- ▶ **Cervical**
- ▶ Liver

Chlamydia trachomatis is associated with a greater risk of invasive cervical cancer



Epidemiology | Free Access

Chlamydia trachomatis and invasive cervical cancer: A pooled analysis of the IARC multicentric case-control study

Jennifer S. Smith, Cristina Bosetti, Nubia Muñoz, Rolando Herrero, F. Xavier Bosch, José Eluf-Neto, Chris J.L.M. Meijer, Adriaan J.C. van den Brule, Silvia Franceschi, Rosanna W. Peeling

First published: 23 April 2004 | <https://doi.org/10.1002/ijc.20257> | Cited by: 118

Read the full text >

PDF TOOLS SHARE

“This study, based on data from 1,238 case and 1,100 control participants in 7 countries worldwide, shows that *C. trachomatis* serum antibodies were associated with a 1.8-fold increased risk of squamous cell invasive cervical cancer.”

Abstract

To determine whether *Chlamydia trachomatis* infection is consistently associated with an increased risk of invasive cervical carcinoma (ICC) after accounting for the strong effect of human papillomavirus (HPV) infection, a case-control study of 1,238 cases of ICC and 1,100 control women from 7 countries was carried out (hospital-based studies in Thailand, the Philippines, Morocco, Peru, Brazil and population-based studies in Colombia and Spain, all coordinated by the International Agency for Research on Cancer, Lyon, France). *C. trachomatis* serum antibody detection was made by means of a microfluorescence assay. Among HPV DNA-positive cases and controls, the risk of squamous cell ICC was elevated in *C. trachomatis* seropositive women (OR = 1.8; 95% CI =

Source: <https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.20257>

Several independent studies suggest that HSV-2 infections correlate with a higher than normal incidence of cervical cancer, and with HPV



Clinical Microbiology
Reviews

Clin Microbiol Rev. 1995 Oct. 8(4): 548-556.
doi: 10.1128/cmr.8.4.549

PMCID: PMC172875
PMID: 8655869

Cervical cancer: is herpes simplex virus type II a cofactor?

C. Jones

• Author information • Copyright and License Information • Disclaimer

This article has been cited by other articles in PMC.

ABSTRACT

In many ways, cervical cancer behaves as a sexually transmitted disease. The major risk factors are multiple sexual partners and early onset of sexual activity. Although high-risk types of human papillomaviruses (HPV) play an important role in the development of nearly all cases of cervical cancer, other sexually transmitted infectious agents may be cofactors. Herpes simplex virus type 2 (HSV-2) is transmitted primarily by sexual contact and therefore has been implicated as a risk factor. Several independent studies suggest that HSV-2 infections correlate with a higher than normal incidence of cervical cancer. In contrast, other epidemiological studies have concluded that infection with HSV-2 is not a major risk factor. Two separate transforming domains have been identified within the HSV-2 genome, but continued viral gene expression apparently is not required for cellular DNA damage. These studies suggest that HSV-2 is a cofactor in the development of cervical cancer. In some but not all

“ HSV infections lead to unscheduled cellular DNA synthesis, chromosomal amplifications, and mutations.”



JOURNAL of the
NATIONAL CANCER INSTITUTE

Issues More Content ▾ Submit ▾ Purchase Alerts About ▾

JNCI: Journal of the

No cover
image
available

Volume 94, Issue 21
6 November 2002

Article Contents

Abstract

SUBJECTS AND METHODS

RESULTS

DISCUSSION

APPENDIX

REFERENCES

• Previous • Next •

JOURNAL ARTICLE

Herpes Simplex Virus-2 as a Human Papillomavirus Cofactor in the Etiology of Invasive Cervical Cancer

Jennifer S. Smith, Rolando Herrero, Cristina Bosetti, Nubia Muñoz, F. Xavier Bosch, José Eluf-Neto, Xavier Castellsagué, Chris J. L. M. Meijer, Adriaan J. C. Van den Brule, Silvia Franceschi ... Show more

JNCI: Journal of the National Cancer Institute, Volume 94, Issue 21, 6 November 2002, Pages 1604-1613, <https://doi.org/10.1093/jnci/94.21.1604>

Published: 06 November 2002 Article history ▾

PDF Split View Cite Permissions Share ▾

Abstract

Background: Human papillomavirus (HPV) infection is the main cause of invasive cervical cancer, but cofactors may act in conjunction with HPV. We performed a pooled analysis of seven case-control studies to examine the effect of one possible HPV cofactor, herpes simplex virus-2 (HSV-2) infection, in the etiology of invasive cervical cancer. **Methods:** Blood and exfoliated cervical specimens were obtained from 1263 case patients with invasive cervical cancer (1158 with squamous-cell carcinomas and 105 with adenocarcinoma or adenosquamous-cell carcinomas) and 1117 age-matched control subjects. Western blot analysis and/or an enzyme-linked immunosorbent assay were

“Among the HPV DNA-positive women, HSV-2 seropositivity was associated with increased risks of squamous-cell carcinoma.”

Tailored testing protocol for the possibility of infection-associated cervical cancer

» Cervical cancer:

1. Chlamydia trachomatis EliSpot and IgG/IgA antibodies
2. HSV I/2 EliSpot and IgG/IgA antibodies

What cancers have infections been associated with?

Part 2:

- ▶ Lung
- ▶ Colorectal
- ▶ Gastric
- ▶ Oesophageal
- ▶ Cervical
- ▶ **Liver**

More than half of the world's cases of liver cancer are due to viral liver infections

OUTLOOK | 30 March 2022

Hepatitis B and the liver cancer endgame

More than half of the world's cases of liver cancer are due to viral liver infections. Detecting and treating hepatitis B could help to reverse the global increase in fatal liver cancer.

Kristina Campbell



Jasim Behary (left) studies changes in the gut microbiome in people who develop liver cancer. Credit: Jasim Behary

“Hepatitis B virus causes cancer by integrating its DNA into human cells. Delving further, his group found that the viral break-ins led to chromosome rearrangements, wiping out genes that suppress tumours and allowing cancer cells to proliferate.”

Source: <https://www.nature.com/articles/d41586-022-00821-0?proof=t>

Most common risk factor for liver cancer is chronic infections with hepatitis B or C



The screenshot shows the Hepatitis B Foundation website. The header includes the logo, navigation links (ABOUT US, QUICK LINKS, CONTACT US, LANGUAGE), a search bar, and a 'Subscribe' button. The main navigation bar lists: What Is Hepatitis B?, Prevention & Diagnosis, Treatment & Management, Resources & Support, Research & Programs, and News & Events. The left sidebar under 'Liver Cancer Connect' lists: Newly Diagnosed, What is Liver Cancer?, Risk Factors (selected), Chronic Viral Hepatitis, Family History of Liver Cancer, Cirrhosis, Heavy Alcohol Use, Aflatoxins and Environmental Toxins, Diabetes, Obesity and Nonalcoholic Fatty Liver Disease, and Ethnicity. The main content area is titled 'Risk Factors' and includes the following text:

What Is a Risk Factor?

A risk factor is anything that increases a person's chance of developing a disease such as cancer. Different cancers have different risk factors. The risk factors do not always directly cause cancer. Some people may have several risk factors but never develop cancer, while other people who have no known risk factors do develop cancer. The more risk factors a person has, the greater the chance of developing cancer.

Knowing your risk factors and discussing them with your health care provider may help you make more informed lifestyle and health care choices about how to reduce your risk of cancer.

What Are the Risk Factors for Liver Cancer?

The most common risk factor for liver cancer globally is chronic infection with the hepatitis B virus. Individuals chronically infected with hepatitis B have a 25% to 40% lifetime risk of developing liver cancer.

In the United States, chronic infection with the hepatitis C virus is the most common risk factor. A greater number of Americans infected with this virus. It is the most common risk factor for liver cancer in the United States. At least 54% of all liver cancer worldwide.

"Individuals chronically infected with hepatitis B have a 25% to 40% lifetime risk of developing liver cancer."

Source: <https://www.cancer.org/cancer/liver-cancer/causes-risks-prevention/risk-factors.html>; <https://www.hepb.org/research-and-programs/liver/risk-factors-for-liver-cancer/#:~:text=The%20most%20common%20risk%20factor,risk%20of%20developing%20liver%20cancer.>

Over half of cases of liver cancer – the 3rd leading cause of cancer deaths globally – are due to viral liver infections



ARTICLE

<https://doi.org/10.1038/s41467-021-26805-8>

OPEN



Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture

Eva G. Álvarez^{1,2}, Jonas Demeulemeester^{3,4,23}, Paula Otero^{1,2,23}, Clemency Jolly^{3,23}, Daniel García-Souto^{1,2,23}, Ana Pequeño-Valtierra¹, Jorge Zamora¹, Marta Tojo⁵, Javier Temes¹, Adrian Baez-Ortega⁶, Bernardo Rodríguez-Martin^{1,2}, Ana Oitaben^{1,2}, Alicia L. Bruzos^{1,2}, Mónica Martínez-Fernández¹, Kerstin Haase³, Sonia Zumalave^{1,2}, Rosanna Abal¹, Jorge Rodríguez-Castro¹, Aitor Rodríguez-Casanova^{7,8}, Angel Díaz-Lagares^{7,9}, Yilong Li¹⁰, Keiran M. Raine¹⁰, Adam P. Butler¹⁰, Iago Otero^{1,2}, Atsushi Ono¹¹, Hiroshi Aikata¹¹, Kazuaki Chayama^{12,13,14}, Masaki Ueno¹⁵, Shinya Hayami¹⁵, Hiroki Yamaue¹⁵, Kazuhiro Maejima¹⁴, Miguel G. Blanco¹, Xavier Fornis¹⁶, Carmen Rivas^{1,17}, Juan Ruiz-Bañobre^{1,9,18,19}, Sofia Pérez-del-Pulgar¹⁶, Raúl Torres-Ruiz^{20,21}, Sandra Rodríguez-Perales²⁰, Urtzi Garaigorta^{17,24}, Peter J. Campbell^{10,22,24}, Hidewaki Nakagawa^{14,24}, Peter Van Loo^{3,24} & Jose M. C. Tubio^{1,2,24}

Worldwide, the most common risk factor for liver cancer is chronic (long-term) infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).

In the US, infection with hepatitis C is the more common cause of hepatocellular carcinoma, while in Asia and developing countries, hepatitis B is more common.

“Tubio’s ... group found that the viral break-ins led to chromosome rearrangements, wiping out genes that suppress tumours and allowing cancer cells to proliferate.”

Source: <https://www.nature.com/articles/d41586-022-00821-0>; Álvarez EG, Tubio JMC et al. Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture. Nat Commun. 2021 Nov 25;12(1):6910;

<https://pubmed.ncbi.nlm.nih.gov/34824211/>; <https://www.cancer.org/cancer/liver-cancer/causes-risks-prevention/risk-factors.html>; <https://www.hepb.org/research-and-programs/liver/risk-factors-for-liver-cancer/#:~:text=The%20most%20common%20risk%20factor,risk%20of%20developing%20liver%20cancer.>

Campylobacter also an association: 38% of patients had liver cancer in a study of 183 patients with C. bacteremia

Journal List > Infect.Chemother > v.49(3).2017.Sep > PMC5620392



Infect.Chemother. 2017 Sep; 49(3): 230-235.

Published online 2017 May 26. doi: [10.3947/ic.2017.49.3.230](https://doi.org/10.3947/ic.2017.49.3.230)

PMCID: PMC5620392

PMID: 28628861

Campylobacter jejuni Bacteremia in a Liver Cirrhosis Patient and Review of Literature: A Case Study

Jin Gu Yoon,¹ Saem Na Lee,¹ Hak Jun Hyun,¹ Min Joo Choi,^{1,2} Ji Ho Jeon,^{1,2} Eunju Jung,^{1,2} Seonghui Kang,^{1,2} Jeeyong Kim,² Ji Yun Noh,^{1,2} Won Suk Choi,^{1,2} Joon Young Song,^{1,2} Hee Jin Cheong,^{2,3} and Woo Joo Kim^{1,2}

• Author information • Article notes • Copyright and License information • Disclaimer

This article has been cited by other articles in PMC.

Abstract

Go to: *

Campylobacter infection causes gastrointestinal symptoms such as abdominal pain or diarrhea. Occasionally, *Campylobacter* bacteremia affects immunocompromised patients; however, serious outcomes are known to be rare. Here, we present a case of a patient with *Campylobacter* bacteremia who had underlying liver cirrhosis. The patient had fever and diarrhea. These symptoms subsided after treatment with cefotaxime. *Campylobacter jejuni* was isolated in the blood culture after 10 days. In addition, previously reported cases of *Campylobacter* bacteremia in Asian countries were reviewed with respect to antimicrobial sensitivities.

JOURNAL ARTICLE

Campylobacter Bacteremia: Clinical Features and Factors Associated with Fatal Outcome

Jérôme Pacanowski¹, Valérie Lalonde, Karine Lacombe, Cherif Boudraa, Philippe Lesprit, Patrick Legrand, David Trystram, Najib Kassir, Guillaume Arlet, Jean-Luc Mainardi ... Show more

Clinical Infectious Diseases, Volume 47, Issue 6, 15 September 2008, Pages 790-796, <https://doi.org/10.1093/cid/cin1530>

Published: 15 September 2008 Article history ▾

PDF Split View Cite Permissions Share ▾

Abstract

Background. *Campylobacter* bacteremia is uncommon. The influence of underlying conditions and of the impact of antibiotics on infection outcome are not known.


Methods. From January 2000 through December 2004, 183 episodes of *Campylobacter* bacteremia were identified in 23 hospitals in the Paris, France, area. The medical records were reviewed. Characteristics of bacteremia due to *Campylobacter jejuni* and to other *Campylobacter* species were compared. Logistic regression analysis was performed to identify risk factors for fatal outcome.

“The main underlying conditions were liver disease (39%) and cancer (38%).”

Source: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620392/>; <https://academic.oup.com/cid/article/47/6/790/325735>

Enteroviruses also associated with liver cancer


National Library of Medicine
 National Center for Biotechnology Information


PubMed Central®

Search PMC Full-Text Archive

Journal List > *Oncol Lett* > v.17(2):2019 Feb > PMC6350183


ONCOLOGY LETTERS
 SPANDIDOS PUBLICATIONS

Oncol Lett. 2019 Feb; 17(2): 2485–2490.
 Published online 2018 Dec 24. doi: [10.3892/ol.2018.9888](https://doi.org/10.3892/ol.2018.9888)

PMCID: PMC6350183
 PMID: 30719117

Expression of coxsackie and adenovirus receptor is correlated with inferior prognosis in liver cancer patients

Xue Yang,^{1,2,*} Shuangshuang Li,^{1,2,*} Huiju Wang,^{1,3} Wanyuan Chen,⁴ Xiaozhou Mou,^{1,2} and Shibing Wang^{1,2}

• Author information • Article notes • Copyright and License Information • Disclaimer



Volume 68, Issue 2
 July 2013

Article Contents

Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Acknowledgements
 References

PATHOGENS AND DISEASE

Issues • More Content • FEMS Journals • Submit • Purchase • About



JOURNAL ARTICLE

Hepatic damage caused by coxsackievirus B3 is dependent on age-related tissue tropisms associated with the coxsackievirus-adenovirus receptor

Jung-Yen Liu, Shih-Min Wang, I-Chun Chen, Chun-Keung Yu, Ching-Chuan Liu

Pathogens and Disease, Volume 68, Issue 2, July 2013, Pages 52–60,
<https://doi.org/10.1111/2049-632X.12044>

Published: 01 July 2013 Article history

 PDF  Split View  Cite  Permissions  Share

Abstract

Coxsackievirus B (CVB) and enterovirus 71 (EV71) are important causes of severe enteroviral diseases in neonates or young children in Taiwan. CVB can cause fulminant hepatitis, myocarditis or meningoencephalitis. This study was designed to explore the role of coxsackievirus-adenovirus receptor (CAR) in the pathogenesis of CVB3-infected hepatocytes via *in vitro* and mice studies. CVB3

The coxsackievirus-adenovirus receptor (CAR) is “expressed more in more in liver than in other tissues ... These findings indicate that CAR plays an important role in the initiation of CVB infections and is closely associated with hepatotropism and age-specific susceptibility”.

Source: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350183/>; <https://academic.oup.com/femspd/article/68/2/52/2398850>


Viral infection history can be used to detect hepatocellular cancer (HCC)

Cell

Article

A Viral Exposure Signature Defines Early Onset of Hepatocellular Carcinoma

Graphical Abstract



Authors


Jinping Liu, Wei Tang, Anuradha Budhu, ..., Zhanwei Wang, Herbert Yu, Xin Wei Wang

Correspondence

xw3u@nih.gov

In Brief

Lui et al. demonstrate how viral infection history, obtained using human blood samples and VirScan analysis of antiviral antibodies, can be used to detect hepatocellular carcinoma in at-risk patients prior to clinical cancer diagnoses.

Cell
Article

Source: [https://www.cell.com/cell/pdf/S0092-8674\(20\)30671-1.pdf](https://www.cell.com/cell/pdf/S0092-8674(20)30671-1.pdf)

Tailored testing protocol for the possibility of infection-associated liver cancer

» Liver cancer:

1. Hepatitis B
2. Hepatitis C
3. Camphylobacter
4. Cocksackie A/B IgG/IgA antibodies

Tailored testing protocols available for all the types of cancer mentioned

Please request from
AONM (0333 121
0305)

Test panels in different cancers

» Lung cancer

Chlamydia pneumoniae EliSpot & IgG/IgA antibodies
Mycoplasma pneumoniae EliSpot & IgG/IgA antibodies
Epstein Barr Virus EliSpot

» Oesophageal cancer

Mycoplasma pneumoniae EliSpot & IgG/IgA antibodies

» Gastric cancer

H. pylori IgG/IgA antibodies
Epstein Barr Virus EliSpot

» Colorectal cancer

H. pylori IgG/IgA antibodies
Epstein Barr Virus EliSpot
Cytomegalovirus EliSpot

» Cervical cancer

Chlamydia pneumoniae EliSpot & IgG/IgA antibodies
Herpes Simplex Virus (HSV) 1/2 EliSpot & IgG/IgA antibodies

» Liver cancer

Hepatitis B antibodies
Hepatitis C antibodies
Campylobacter IgG/IgA antibodies
Coxsackie A & B IgG/IgA antibodies

Further presentations on the links between pathogens and cancer available from AONM

Tick-borne diseases and viruses in cancer and unexplained syndromes

Armin Schwarzbach PhD

AONM Conference May 2017

Medical doctor and

Specialist for laboratory medicine

Augsburg



This document is intellectual property of Armin Schwarzbach MD PhD.
Reproduction only with permission. Please note the copyright.

See <https://aonm.org/cancer-webinar-series/>

Infectious Pathogens and Cancer: The Emerging Evidence

Armin Schwarzbach MD PhD

AONM Conference March 2018

Medical doctor and
Specialist for laboratory medicine
Augsburg, Germany




This document is intellectual property of Armin Schwarzbach MD PhD.
Reproduction only with permission. Please note the copyright.



This document is intellectual property of Armin Schwarzbach MD PhD.
Reproduction only with permission. Please note the copyright.

Professor Sapi gave us incredible insights into the possible links between Borrelia and breast cancer



<https://aonm.org/view-past-webinars/>

Thank you very much for your attention!



For tests, please go to
www.aonm.org
<https://aonm.org/arminlabs>

or call the AONM helpline
on 0333 121 0305

